Therefore, at this point, it is difficult to make definitive recommendations regarding the optimal cut-off points for C-MYC for general use, as these needs to be validated in large prospective cohorts of DLBCL patients. The gene discussed is MYC; the disease is diffuse large B-cell lymphoma.